Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome

Pathophysiology

Volumn 18, Issue 1, 2011, Pages 93-102

  Erkan, Doruk ^a,b,c   Kozora, Elizabeth ^b,d,e   Lockshin, Michael D ^a,b,c  

^a The Barbara Volcker Center for Women and Rheumatic Disease   (United States)

^b Hospital for Special Surgery   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d DEPARTMENT OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antiphospholipid syndrome; Cognitive dysfunction; White matter abnormalities

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; THROMBIN INHIBITOR; WARFARIN;

ANTIBODY TITER; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ATTENTION DISTURBANCE; BLEEDING; BRAIN ATROPHY; BRAIN ISCHEMIA; COGNITIVE DEFECT; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; FETUS DEATH; HUMAN; LOW DRUG DOSE; MOLECULAR MIMICRY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER;

EID: 78650525662     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2010.04.010     Document Type: Review

References (78)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J. Thromb. Haemost. 2006, 4:295-306.
2. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999, 42:1309-1311.
3. Sanna G., Bertolaccini M.L., Cuadrado M.J., Liang H., Khamashta M.A. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 2003, 30:985-992.
4. Erkan D., Lockshin M.D. New approaches to the management of Antiphospholipid Syndrome. Nat. Clin. Pract. Rheumatol. 2009, 5:160-170.
5. Erkan D., Lockshin M.D. What is antiphospholipid syndrome?. Curr. Rheumatol. Rep. 2004, 6:451-457.
6. Gharavi A.E., Pierangeli S.S., Harris E.N. Origin of antiphospholipid antibodies. Rheum. Dis. Clin. North Am. 2001, 27:551-563.
7. Blank M., Krause I., Fridkin M., Keller N., Kopolovic J. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J. Clin. Invest. 2002, 109:797-804.
8. Gharavi A.E., Sammaritano L.R., Wen J., Elkon K.B. Induction of antiphospholipid antibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J. Clin. Invest. 1992, 90:1105-1109.
9. Kamboh M.I., Manzi S., Mehdi H., Fitzgeral S., Sanghera D.K. Genetic variation in apolipoprotein H (beta2-glycoprotein I) affects the occurrence of antiphospholipid antibodies and apolipoprotein H concentrations in systemic lupus erythematosus. Lupus 1999, 8:742-750.
10. Bancsi L.F., Van der Linden I.K., Bertina R.M. B2-glycoprotein I deficiency and the risk of thrombosis. Thromb. Haemost. 1992, 67:649-653.
11. Sheng Y., Reddel S.W., Herzog H., Wang Y.X., Brighton T. Impaired thrombin generation in beta 2-glycoprotein I null mice. J. Biol. Chem. 2001, 276:13817-13821.
12. Nojima J., Suehisa E., Kuratsune H., Machii T., Koike T. Platelet activation induced by combined effects of anticardiolipin and lupus anticoagulant IgG antibodies in patients with systemic lupus erythematosus-possible association with thrombotic and thrombocytopenic complications. Thromb. Haemost. 1999, 81:436-441.
13. Smirnov M.D., Triplett D.T., Comp P.C., Esmon N.L., Esmon C.T. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J. Clin. Invest. 1995, 95:309-316.
14. Rand J.H., Wu X.X., Guller S., Andree H.A., Lockwood C.J. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am. J. Obstet. Gynecol. 1997, 177:918-923.
15. Roubey R.A. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum. 2003, 48:3004-3008.
16. Potti A., Bild A., Dressman H.K., Lewis D.A., Nevins J.R. Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood 2006, 107:1391-1396.
17. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 2003, 112:1644-1654.
18. Oshiro B.T., Silver R.M., Scott J.R., Yu H., Branch D.W. Antiphospholipid antibody and fetal death. Obstet. Gynecol. 1996, 87:489-493.
19. Asherson R.A., Cervera R., de Groot P., Erkan D., Boffa M.C. Catastrophic Antiphospholipid Syndrome (CAPS): International Consensus Statement on Classification Criteria and Treatment Guidelines. Lupus 2003, 12:530-534.
20. Brandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb. Haemost. 1995, 74:1185-1190.
21. Galli M., Luciani M., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:827-1132.
22. Crowther M.A., Ginsberg J.S., Julian J., Denburg J., Hirsch J. Comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 2003, 349:1133-1138.
23. Finazzi G., Marchioli R., Brancaccio V., Schinco P., Wisloff F. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 2005, 3:848-853.
24. Levine S.R., Brey R.L., Tilley B.C., Thompson J.L., Sacco R.L. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004, 291:576-584.
25. Erkan D., Harrison M.J., Levy R., Peterson R.M., Petri M. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007, 56:2382-2391.
26. West S.G Neuropsychiatric lupus. Rheum. Dis. Clin. North Am. 1994, 20:129-158.
27. Carbotte R.M., Denburg S.D., Denburg J.A. Prevalence of cognitive impairment in systemic lupus erythematosus. J. Nerv. Ment. Dis. 1986, 174:357-364.
28. Hanly J.G., Walsh N.M., Fisk J.D., Eastwood B., Hong C., Sherwood G. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br. J. Rheumatol. 1993, 32:291-296.
29. Glanz B.I., Slonim D., Urowitz M.B., Gladman D.D., Gough J. Pattern of neuropsychologic dysfunction in inactive systemic lupus erythematosus. Neuropsychol. Behav. Neurol. 1997, 10:232-238.
30. Ginsburg K.S., Wright E.A., Larson M.G., Fossel A.H., Albert M. A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum. 1992, 35:776-782.
31. Denburg S.D., Carbotte R.M., Denburg J.A. Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. J. Clin. Exp. Neuropsychol. 1987, 9:323-339.
32. The American College of Rheumatology Nomenclature and Case Definitions for Neuropsychiatric Lupus Syndromes. Arthritis Rheum. 1999, 42:599-608.
33. Kozora E., Thompson L.L., Cullum C.M. A pilot study evaluating neuropsychological and psychological status of patients with systemic lupus erythematosus (SLE). J. Clin. Exp. Neuropsychol. 1991, 13:59-60.
34. Stein H., Walters K., Dillon A., Schulzer M. Systemic lupus erythematosus-a medical and social profile. J. Rheumatol. 1986, 13:570-576.
35. Sonies B.C., Klippel J.H., Gerber R.B., Gerber C.H. Cognitive performance in systemic lupus erythematosus. Arthritis Rheum. 1982, 25:S80. (abstract).
36. Brey R.L., Holliday S.L., Saklad A.R., Navarrete M.G., Hermosillo-Romo D. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002, 58:1214-1220.
37. Kozora E., Thompson L.L., West S.G., Kotzin B.L. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1996, 39:2035-2045.
38. Maeshima E., Yamada Y., Yukawa S., Nomoto H. Higher cortical dysfunction, antiphospholipid antibodies, and neuroradiological examinations in systemic lupus erythematosus. Intern. Med. 1992, 31:1169-1174.
39. Denburg S.D., Carbotte R.M., Denburg J.A. Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J. Rheumatol. 1997, 24:998-1003.
40. Denburg S.D. Cognitive correlates of antiphospholipid antibody positivity in SLE. Arthritis Rheum. 1993, 36:S103. (abstract).
41. Leritz E., Brandt J., Minor M., Reis-Jensen F., Petri M. Subcortical cognitive impairment in patients with systemic lupus erythematosus. J. Int. Neuropsychol. Soc. 2000, 6:821-825.
42. Carlomagno S., Migliaresi S., Ambrosone L., Sannino M., Sanges G. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J. Neurol. 2000, 247:273-279.
43. Holliday S.L., Navarete G., Escalante A., Saklad A.R., BreY R.L. Demographic, symptomatic, and serologic predictors of cognitive function in systemic lupus erythematosus: preliminary results from SALUD. J. Int. Neuropsychol. Soc. 2000, 6:231-232. (abstract).
44. Waterloo K., Omdal R., Husby G., Mellgren S.I. Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology (Oxford) 2002, 41:411-415.
45. Waterloo K., Omdal R., Sjoholm H., Koldingsnes W., Jacobsen E.A. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J. Neurol. 2001, 248:595-602.
46. Hanly J.G., Cassell K., Fisk J.D. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum. 1997, 40:1542-1543.
47. Jacobson M.W., Rapport L.J., Keenan P.A., Coleman R.D., Tietjen G.E. Neuropsychological deficits associated with antiphospholipid antibodies. J. Clin. Exp. Neuropsychol. 1999, 21:251-264.
48. Tektonidou M.G., Varsou N., Kotoulas G., Antoniou A., Moutsopoulos H.M. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch. Intern. Med. 2006, 166:2278-2284.
49. Chapman J., Abu-Katash M., Inzelberg R., Yust I., Neufeld M.Y., Vardinon N. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J. Neurol. Sci. 2002, 203:81-84.
50. Schmidt R., Auer-Grumbach A., Fazekas F., Offenbacher H., Kapeller P. Anticardiolipin antibodies in normal subjects: neuropsychological correlates and MRI findings. Stroke 1995, 26:749-754.
51. De Moorlose P., Boehlen F., Rebe G. Prevalence of anticardiolipin and antinuclear antibodies in an elderly hospitalized population and mortality after a 6-year follow-up. Age Aging 1997, 26:319-320. (letter).
52. Cesbron J.Y., Amouyel P., Masy E. Anticardiolipin antibodies and physical disability in elderly. Ann. Intern. Med. 1997, 126:1003. (letter).
53. Caront B., Calderaro C., Alessandri C., Conti C., Tinghino F.R. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J. Autoimmun. 1998, 11:425-429.
54. Chapman J., Cohen-Armon M., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999, 8:127-133.
55. Katzav A., Pick C.G., Korczyn A.D., Oest E., Blank M., Shoenfeld Y., Chapman J. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
56. Ziporen L., Shoenfeld Y., Levy Y., Korczyn A.D. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J. Clin. Invest. 1997, 100:613-619.
57. Shoenfeld Y., Nahum A., Korczyn A.D., Dano M., Rabinowitz R. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003, 12:436-442.
58. Gomez-Puerta J.A., Cervera R., Calvo L.M., Gomez-Anson B., Espinosa G. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology (Oxford) 2005, 44:95-99.
59. Lampropoulos C.E., Koutroumanidis M., Reynolds P.P., Manidakis I., Hughes G.R. Electroencephalography in the assessment of neuropsychiatric manifestations in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum. 2005, 52:841-846.
60. Aisen A.M., Gabrielsen T.O., McCune W.J. MR imaging of systemic lupus erythematosus involving the brain. Am. J. Roentgenol. 1985, 144:1027-1031.
61. Kozora E., Make B. Neuropsychological effects of rehabilitation in patients with chronic obstructive pulmonary disease (COPD): a pilot study. 1998 American Psychological Association Meeting 1998.
62. Ishikawa O., Ohnishi K., Miyachi Y., Ishizaka H. Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging. Relationship to anticardiolipin antibody. J. Rheumatol. 1994, 21:87-90.
63. Fields R.A., Sibbitt W.L., Toubbeh H., Bankhurst A.D. Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. Ann. Rheum. Dis. 1990, 49:114-117.
64. Davie C.A., Feinstein A., Kartsounis L.D., Barker G.J., McHugh N.J. Proton magnetic resonance spectroscopy of systemic lupus erythematosus involving the central nervous system. J. Neurol. 1995, 242:522-528.
65. Sibbitt W.L., Sibbitt R.R., Brooks W.M. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 1999, 42:2026-2038.
66. Jarek M.J., West S.G., Baker M.R., Rak K.M. Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus. Arthritis Rheum. 1994, 37:1609-1613.
67. Gonzalez-Crespo M.R., Blanco F.J., Ramos A., Ciruelo E., Mateo I., Lopez-Pino M.A. Magnetic resonance imaging of the brain in systemic lupus erythematosus. Br. J. Rheum. 1995, 34:1055-1060.
68. Kozora E., Arciniegas D.B. Brain abnormalities in SLE patients with cognitive impairment. Arthritis Rheum. 2006, 54:S273. (abstract).
69. Filley C.M., Kozora E., Brown M.S., Miller D.E., West S. White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus. Cogn. Behav. Neurol. 2009, 22:38-44.
70. Zhang L., Harrison M., Heier L.A., Zimmerman R.D., Ravdin L. Diffusion changes in patients with systemic lupus erythematosus. Magn. Reson. Imaging 2007, 25:399-405.
71. Ellis C.M., Simmons A., Jones D.K., Bland J., Dawson J.M. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology 1999, 53:1051-1058.
72. Ulug A.M., Grunewald T., Lin M.T., Kamal A.K., Filippi C.G. Diffusion tensor imaging in the diagnosis of primary lateral sclerosis. J. Magn. Reson. Imaging 2004, 19:34-39.
73. Andrade R.E., Gasparetto E.L., Cruz L.C., Ferreira F.B., Domingues R.C. Evaluation of white matter in patients with multiple sclerosis through diffusion tensor magnetic resonance imaging. Arq. Neuropsiquiatr. 2007, 65:561-564.
74. Benedict R.H., Bruce J., Dwyer M.G., Weinstock-Guttman B., Tjoa C. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult. Scler. 2007, 13:722-730.
75. Lin X., Tench C.R., Morgan P.S., Constantinescu C.S. Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2007, 79:437-441.
76. RovariS M., Filippi M. Diffusion tensor MRI in multiple sclerosis. J. Neuroimaging 2007, 17S:27S-30S.
77. Difrancesco M.W., Holland S.K., Ris M.D., Adler C.M. Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. Arthritis Rheum. 2007, 56:4151-4163.
78. Fitzgibbon B.M., Fairhall S.L., Kirk I.J., Kalev-Zylinska M. Functional MRI in NPSLE patients reveals increased parietal and frontal brain activation during a working memory task compared with controls. Rheumatology (Oxford) 2008, 47:50-53.